Consistent with the effect of the IGF1R inhibitor linsitinib, shASS1/PYCR1 demonstrated a synergistic effect on tumour-proliferation inhibition with DDP in vitro (Fig. 6H-I) and in vivo (Fig. 6J-L). This evidence concerns the gene PYCR1 and neoplasm.